Jul 04th 2012 - Edison Investment Research today published a report on SkyePharma (SKP.L, LSE:SKP, LON:SKP) entitled "Hallelujah". In summary, the report says:
The European Commission’s adoption of a legally binding decision in favour of granting marketing authorisations for Flutiform effectively marks the conclusion of the tortuous EU regulatory process and prompted a 30% rally in the shares yesterday. Flutiform’s launch by Mundipharma in the initial EU markets – the UK and Germany – can now be assumed for late Q3. The EU approval and launch is an essential condition for SkyePharma to restructure its balance sheet, and, once achieved, this should mean shareholders at last see returns that reflect its operating performance.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
